CVS Health reported a strong Q4 2025 performance, with revenue growing 8% year-over-year to $105.7 billion and adjusted EPS exceeding forecasts, despite a decline in gross margin. The company saw significant growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. While profitability faced challenges, diluted EPS rose due to a tax benefit, and analysts maintain a positive outlook for CVS stock.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
CVS Health Reports Q4 Beat but Maintains Full-Year Outlook
CVS Health reported a strong Q4 2025 performance, with revenue growing 8% year-over-year to $105.7 billion and adjusted EPS exceeding forecasts, despite a decline in gross margin. The company saw significant growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. While profitability faced challenges, diluted EPS rose due to a tax benefit, and analysts maintain a positive outlook for CVS stock.